Stifel initiates coverage on Inozyme Pharma with a Buy rating and a $16 price target, highlighting INZ-701's potential to treat rare diseases like ENPP1 and ABCC6 deficiencies.
As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free
Inozyme Pharma Inc (NASDAQ: INZY) announced interim safety, pharmacokinetic (PK), pharmacodynamic (PD), and exploratory efficacy data from its ongoing Phase 1/2 trials of INZ-701 in adults with
Following meetings with the FDA and the European Medicines Agency's Paediatric Committee, Inozyme Pharma Inc (NASDAQ: INZY) updated its global development strategy for INZ-701, a
Inozyme Pharma (NASDAQ:INZY) reported its Q1 earnings results on Tuesday, May 9, 2023 at 08:30 AM. Here's what investors need to know about the announcement. Earnings Inozyme Pharma beat estimated earnings by 11.11%, reporting an EPS of $-0.4 versus an estimate of $-0.45.
